Concepedia

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma

Zachary J. Brown, Su Jong Yu, Bernd Heinrich, Chi Ma, Qiong Fu, Milan Sandhu, David Agdashian, Qianfei Zhang, Firouzeh Korangy, Tim F. Greten

Cancer Immunology Immunotherapy · 2018 · 111 citations · 31 references

DOIFull text

Open access

Concepts

References

31

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

, , +17

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

, , +13

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

, , +17

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Catherine Uyttenhove, Luc Pilotte, Ivan Théate et al. · Nature Medicine · 2003 · 2.3K citations

, , +11

Up-Regulation of PD-L1, IDO, and T <sub>regs</sub> in the Melanoma Tumor Microenvironment Is Driven by CD8 <sup>+</sup> T Cells

Stefani Spranger, Robbert M. Spaapen, Yuanyuan Zha et al. · Science Translational Medicine · 2013 · 1.7K citations · Full text

, , +17